REPIRINAST

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H21NO5
Molecular Weight	355.3844
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)CCOC(=O)C1=CC(=O)C2=C(O1)C3=CC=C(C)C(C)=C3NC2=O

InChI

InChIKey=NFQIAEMCQGTTIR-UHFFFAOYSA-N

InChI=1S/C20H21NO5/c1-10(2)7-8-25-20(24)15-9-14(22)16-18(26-15)13-6-5-11(3)12(4)17(13)21-19(16)23/h5-6,9-10H,7-8H2,1-4H3,(H,21,23)

HIDE SMILES / InChI

Molecular Formula	C20H21NO5
Molecular Weight	355.3844
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://en.pharmacodia.com/web/drug/1_10074.html
Curator's Comment: Description was created based on several sources, including http://www.kegg.jp/dbget-bin/www_bget?dr:D01890 and https://www.ncbi.nlm.nih.gov/pubmed/1331217

Repirinast is an antiallergic drug developed and introduced into the market in Japan in 1987. It is a histamine release inhibitor. It has demonstrated effectiveness for treating bronchial asthma in humans.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Eosinophilia 1 Target ID: Eosinophilia Sources: https://www.ncbi.nlm.nih.gov/pubmed/8386963	Inhibitor 8297
Neutrophilia 1 Target ID: Neutrophilia Sources: https://www.ncbi.nlm.nih.gov/pubmed/8386963	Inhibitor 8297
leukotriene B4 biosynthetic process 7 Target ID: GO:0097251 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2155337	Inhibitor 8297	100.0 µM [IC50]
histamine secretion 4 Target ID: GO:0001821 Sources: http://adisinsight.springer.com/drugs/800001456	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Asthma 241 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1331217	Primary		Approved 8429	Romet Approved Use Asthma

PubMed

Title	Date	PubMed
A late cutaneous response in actively sensitized rats: a new method for evaluating the efficacy of antiallergic drugs.	2006 Aug	16891762

Patents

Sample Use Guides

In Vivo Use Guide

For the treatment of atopic asthma - 300 mg twice daily for 7 days

Route of Administration: Oral

In Vitro Use Guide

Formations of leukotriene B4 by neutrophils activated with a calcium ionophore (A23187) were effectively inhibited at concentrations 20-200 uM.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:31:58 UTC 2023` Edited by `admin` on `Fri Dec 15 15:31:58 UTC 2023`
Record UNII	4K8KA8B61G
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

REPIRINAST

Official Name

English

REPIRINAST [USAN]

Common Name

English

Repirinast [WHO-DD]

Common Name

English

REPIRINAST [MI]

Common Name

English

REPIRINAST [JAN]

Common Name

English

MY-5116

Code

English

repirinast [INN]

Common Name

English

REPIRINAST [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29578